Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ebi, N
Right arrow Articles by Kodama, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ebi, N
Right arrow Articles by Kodama, T
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology, Vol 27, Issue 3 166-169, Copyright © 1997 by Foundation for Promotion of Cancer Research

CASE REPORTS

Second-line chemotherapy for relapsed small cell lung cancer

N Ebi, K Kubota, Y Nishiwaki, F Hojo, T Matsumoto, R Kakinuma, H Ohmatsu, I Sekine, M Yokosaki, K Gotoh, H Yamamoto and T Kodama
Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.

Between January 1985 and August 1991, 159 patients with small cell lung cancer received first-line chemotherapy and 123 (77%) were responders. Of these, 88 relapsed, the remainder having died of other or unknown diseases or being alive without carrying cancer. The relapsed patients were examined to evaluate the outcome of the treatment for relapsed small cell lung cancer and to identify the factors that would contribute to the response rates and the survival durations. Forty-eight of 88 relapsed patients received second-line chemotherapy. Of the 48, 3 were evaluated as showing a complete response, 13 as partial response, 9 as no change, 15 as progressive disease and 8 as not evaluable. The response rate was 33% (95% confidence interval 20.4-48.4%). The median survival time was 146 days. The duration and rate of response in first-line chemotherapy affected the response rates of the second-line chemotherapy, but without statistical significance (P = 0.058 and 0.067 respectively). Increased response duration, time off chemotherapy and previous response to first-line chemotherapy all had a positive effect on the survival times (P < 0.01). Relapsed small cell lung cancer still shows a response to second-line chemotherapy without lessening survival time, and thus clinical trials of new drugs or combination chemotherapeutic regimens for relapsed small cell lung cancer cases would be reasonably justified. Randomized comparative studies are warranted for determining the benefits of second-line chemotherapy for relapsed small cell lung cancer cases.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. R. Eckardt, D. L. Bentsion, O. N. Lipatov, I. S. Polyakov, F. R. MacKintosh, D. A. Karlin, G. S. Baker, and H. B. Breitz
Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
J. Clin. Oncol., April 20, 2009; 27(12): 2046 - 2051.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.